Second, the absence of key clinical data—such as ALT, AST, HBV genotype, liver fibrosis scores, BMI, insulin resistance (e.g., HOMA-IR), and lifestyle factors—raises the risk of residual confounding [48,49,50]. This evidence concerns the gene GPT and Hepatic fibrosis.